FDA Approves New Treatment for Aggressive Breast Cancer

Women diagnosed with the most aggressive form of breast cancer now have a treatment that could extend their lives by years instead of months.

The FDA recently approved Trodelvy as a first-line treatment for metastatic triple-negative breast cancer, the fastest-progressing subtype of the disease. Research conducted at Emory University's Winship Cancer Institute played a key role in making this approval possible.

"There was a time where we weren't seeing patients with metastatic triple negative breast cancer even necessarily living a year," said Dr. Kevin Kalinsky, director of the center's Division of Medical Oncology. Now, patients receiving treatment earlier in their diagnosis are showing significantly better outcomes.

Triple-negative breast cancer affects about 250 of the 1,000 patients Emory's Winship Cancer Institute treats each year. Non-Hispanic Black women face disproportionately higher rates of this aggressive cancer compared to other groups.

The newly approved treatment works like a GPS for cancer cells. It combines an immune-boosting drug with an antibody that targets a specific protein on cancer cells, delivering chemotherapy directly where it's needed most.

Both drugs in the combination had previously received FDA approval separately. But Kalinsky's research revealed something crucial: giving this combination to newly diagnosed patients works better than waiting.

Why This Inspires

More than 75,000 breast cancer patients across 60 countries have already received Trodelvy over the past six years. The drug's track record, combined with the new approval for first-line use, means doctors now have a proven weapon against a cancer that once offered few options and little hope.

For women facing a triple-negative diagnosis today, the prognosis looks dramatically different than it did just a few years ago. What was once measured in months can now be measured in years.

This breakthrough shows how targeted research at institutions like Emory can transform survival rates for even the most challenging cancers.